Core Viewpoint - The article discusses a groundbreaking strategy for cancer vaccines called "degradable vaccines," developed by a team from Peking University, which aims to address the challenge of immune tolerance in cancer treatment [1][5]. Group 1: Innovation in Cancer Vaccines - The degradable vaccine iVAC is designed to strip tumors of their "invisibility cloak" and awaken the body's dormant immune response [5]. - iVAC has shown superior anti-tumor effects compared to traditional immune checkpoint blockade therapies, as evidenced by successful tumor growth suppression in various experimental models [5][6]. - The research addresses a critical issue in cancer vaccines: the difficulty of targeting tumors that lack unique "identity tags" recognized by the immune system [8][9]. Group 2: Mechanism of Action - The innovative approach involves inserting an "attack flag" directly into tumors rather than relying on identifying their unique markers [9]. - iVAC functions like a "Trojan horse," binding to tumor cells and facilitating the internalization of immune-stimulating components while degrading the tumor's defensive proteins [12][13]. - This process effectively reprograms silent cancer cells into active immune messengers, significantly enhancing T-cell activation and promoting a positive feedback loop for immune response [13]. Group 3: Clinical Development and Future Prospects - The research team is actively advancing clinical translation of the iVAC technology, with a focus on personalized cancer vaccines tailored to individual patients [15]. - The global cancer vaccine field is at a pivotal point, shifting from generic vaccines to personalized solutions, while exploring combinations with immune checkpoint inhibitors and cell therapies [15]. - Challenges such as cost and manufacturing processes remain significant barriers to widespread adoption of these innovative therapies [15].

Core Viewpoint - The article discusses a novel approach to cancer immunotherapy through the development of an intratumoral vaccination chimera (iVAC) that combines immune checkpoint degradation with high-quality antigen presentation, aiming to enhance anti-tumor immunity and overcome immune evasion by tumors [4][5][7]. Group 1: Mechanisms of Tumor Immune Evasion - Tumors evade immune surveillance through various mechanisms, including the overexpression of inhibitory checkpoint proteins and impaired antigen presentation [3]. - The lack or dysfunction of tumor-specific cytotoxic T lymphocytes (CTLs) limits the response rates to immune checkpoint blockade (ICB) therapies [3]. Group 2: Development of iVAC - The research team developed the iVAC, which covalently links PD-L1 degradation agents with immunogenic antigens, enabling the reprogramming of tumor cells into antigen-presenting cell-like states [5][7]. - iVAC induces strong tumor-killing effects by reactivating resident antigen-specific CD8+ T cells and reshaping the tumor microenvironment to promote durable tumor-specific immunity [5][7]. Group 3: Experimental Validation - The iVAC technology was validated using antigens derived from cytomegalovirus (CMV) to activate CMV-specific T cells targeting breast cancer in vitro, in humanized mouse models, and in patient-derived tumor models [7]. - This innovative strategy transforms tumor cells into allies of the immune system, paving the way for more effective cancer immunotherapies [7].